Joëlle Benessiano

Title: Joëlle Benessiano: Innovator in Cardiac Risk Assessment

Introduction

Joëlle Benessiano is a notable inventor based in Paris, France. He has made significant contributions to the field of medical diagnostics, particularly in assessing cardiac risks. His innovative approach has the potential to improve patient outcomes by identifying individuals at increased risk of mortality or cardiac events.

Latest Patents

Joëlle Benessiano holds a patent for a method that determines an increased risk of mortality or a cardiac and/or vascular event in a patient. This method involves several steps, including determining the sPLA2 activity of the patient as a first risk marker. Additionally, it requires determining the value of a second risk marker, which may include CRP level, IgM IC of apo B 100 level, or IgM MDA-LDL level. The process also includes calculating the odds ratio between the sPLA2 activity and the second risk marker, comparing it to a predetermined odds ratio. This comparison indicates an increased risk of mortality or cardiac events. Furthermore, he has developed a new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2.

Career Highlights

Throughout his career, Joëlle Benessiano has worked with prestigious organizations such as Assistance Publique-Hôpitaux de Paris and the Institut National de la Santé et de la Recherche Médicale. His work in these institutions has allowed him to advance his research and contribute to the medical community.

Collaborations

Joëlle has collaborated with esteemed colleagues, including Alain Tedgui and Ziad Mallat. These partnerships have enriched his research and fostered innovation in the field of cardiac risk assessment.

Conclusion

Joëlle Benessiano's contributions to medical diagnostics, particularly in assessing cardiac risks, highlight his role as an influential inventor. His patented methods and collaborations with leading professionals underscore the importance of innovation in improving patient care.